OSAKA, Japan & CAMBRIDGE, Mass. - Friday, 17. July 2026 AETOSWire Print On average, about 75% of patients with scalp psoriasis treated with zasocitinib achieved clear or almost clear skin at week 16 Approximately 70% of patients with palmoplantar disease treated with zasocitinib achieved clear or almost clear skin at week 16 Zasocitinib demonstrated statistically significant improvements in Nail Psoriasis Severity Index (NAPSI) versus placebo Results reinforce the potential of zasocitinib to deliver rapid and durable skin clearance, including in the hardest-to-treat areas, in a convenient once-daily pill (BUSINESS WIRE) -- Takeda (TSE:4502/NYSE:TAK) announced new data from the two pivotal Phase 3 studies of zasocitinib (TAK-279), a next-generation, highly selective and potent oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented at the 2026 American Academy of Dermatology (AAD) Innovation Academy, these seco ... Read more »

(BUSINESS WIRE)--AIDS Healthcare Foundation (AHF) welcomed the African Union’s focus on debt sustainability at this week’s Specialized Technical Committees session in Abidjan, Côte d’Ivoire, while urging African leaders to continue pushing for structural reforms to a global debt system that prevents developing countries from investing in healthcare, education, and other basic human needs. The Abidjan talks build on the Common African Position on Debt adopted by African Heads of State in February. Today, 3.4 billion people live in countries that spend more on debt servicing than on health or education. In Africa, two out of every three countries spend more servicing debt than investing in the health of their people, while developing nations face borrowing costs two to ten times higher than those of wealthier countries. A unified African voice on debt reflects the goals of AHF’s global Freedom from Debt campaign, which calls on global leaders to: Support implementation of the Borro ... Read more »